Detailed Information

Cited 0 time in webofscience Cited 0 time in scopus
Metadata Downloads

Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150)

Authors
Jung, Sung-HoonLee, Je-JungKim, Jin SeokMin, Chang-KiKim, KihyunChoi, YunsukEom, Hyeon-SeokJoo, Young DonKim, Sung-HyunKwak, Jae-YongKang, Hye JinLee, Jae HoonLee, Ho SupMun, Yeung-ChulMoon, Joon HoSohn, Sang KyunPark, Seong KyuPark, YongShin, Ho-JinYoon, Sung-Soo
Issue Date
5월-2018
Publisher
ELSEVIER SCIENCE INC
Keywords
Intravenous busulfan; Melphalan; Multiple myeloma; Autologous transplantation
Citation
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, v.24, no.5, pp.923 - 929
Indexed
SCIE
SCOPUS
Journal Title
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
Volume
24
Number
5
Start Page
923
End Page
929
URI
https://scholar.korea.ac.kr/handle/2021.sw.korea/75605
DOI
10.1016/j.bbmt.2018.01.004
ISSN
1083-8791
Abstract
This prospective study evaluated the efficacy and toxicity of intravenous busulfan and melphalan as a conditioning regimen for autologous stern cell transplantation (ASCT) in patients with multiple myeloma (MM). A total of 99 patients with MM, enrolled between January 2013 and March 2016, received intravenous busulfan (9.6 mg/kg) and melphalan (140 mg/m(2)) before ASCT. The median time to transplant was 6.2 months, and 90 (90.9%) patients underwent ASCT within 12 months of the diagnosis. The overall response rate after ASCT was 94.0%, including 43.5% with a stringent complete response/complete response, 27.3% with very good partial response, and 23.2% with partial response. The most common severe nonhematologic toxicity (grade 3 to 4) was infection (26.3%) and stomatitis (15.2%). Three (3.2%) patients developed veno-occlusive disease. No treatment-related mortality was observed. After a median follow-up of 26.1 months, the median progression free survival was 27.2 months (range, 13.0 to 41.4 months) and median overall survival was not reached. In conclusion, a conditioning regimen of intravenous busulfan and melphalan was effective and tolerable. ClinicalTrials.gov. number: NCT01923935 (C) 2018 American Society for Blood and Marrow Transplantation.
Files in This Item
There are no files associated with this item.
Appears in
Collections
College of Medicine > Department of Medical Science > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Park, Yong photo

Park, Yong
의과대학 (의학과)
Read more

Altmetrics

Total Views & Downloads

BROWSE